Literature DB >> 21643928

The management of chronic kidney disease and end-stage renal disease in Nigeria.

Emmanuel I Agaba, Antonios H Tzamaloukas.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21643928     DOI： 10.1007/s11255-011-0004-0

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


× No keyword cloud information.
  7 in total

1.  World kidney day.

Authors:  Dimitrios G Oreopoulos; Antonios Tzamaloukas
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

2.  Self-reported screening of nephrologists for chronic kidney disease: a nationwide survey.

Authors:  Emmanuel I Agaba; Manmak H Mamven; Patricia A Agaba; Antonios Helias Tzamaloukas
Journal:  Int Urol Nephrol       Date:  2009-03-06       Impact factor: 2.370

Review 3.  The epidemiology of end-stage renal disease in Nigeria: the way forward.

Authors:  M O Odubanjo; A O Oluwasola; S Kadiri
Journal:  Int Urol Nephrol       Date:  2011-02-15       Impact factor: 2.370

4.  Inadequacy of dialysis, chronic inflammation and malnutrition in Nigerian patients on chronic hemodialysis.

Authors:  A H Tzamaloukas; D J Vanderjagt; E I Agaba; I Ma; A Lopez; R A Tzamaloukas; G H Murata; R H Glew
Journal:  Int J Artif Organs       Date:  2006-11       Impact factor: 1.595

5.  Hydration abnormalities in Nigerian patients on chronic hemodialysis.

Authors:  Antonios H Tzamaloukas; Aideloje Onime; Emmanuel I Agaba; Dorothy J Vanderjagt; Irene Ma; Andrea Lopez; Rolinda A Tzamaloukas; Robert H Glew
Journal:  Hemodial Int       Date:  2007-10       Impact factor: 1.812

6.  The practice of dialysis in the developing countries.

Authors:  Vivekanand Jha; Kirpal S Chugh
Journal:  Hemodial Int       Date:  2003-06-01       Impact factor: 1.812

7.  Chronic hemodialysis in a Nigerian teaching hospital: practice and costs.

Authors:  E I Agaba; A Lopez; I Ma; R Martinez; R A Tzamaloukas; D J Vanderjagt; R H Glew; A H Tzamaloukas
Journal:  Int J Artif Organs       Date:  2003-11       Impact factor: 1.595
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.